 BOSTON, Oct. 28, 2020 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq:RYTM, a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Jennifer Chien has been appointed as Executive Vice President, Head of North America, effective November 9, 2020. As EVP North America, Ms. Chien will co-lead global integrated commercial strategies in close collaboration with Yann Mazabraud, who was recently appointed EVP, Head of International. 